The future of immune checkpoint therapy

@article{Sharma2015TheFO,
  title={The future of immune checkpoint therapy},
  author={Padmanee Sharma and James P. Allison},
  journal={Science},
  year={2015},
  volume={348},
  pages={56 - 61}
}
Immune checkpoint therapy, which targets regulatory pathways in T cells to enhance antitumor immune responses, has led to important clinical advances and provided a new weapon against cancer. This therapy has elicited durable clinical responses and, in a fraction of patients, long-term remissions where patients exhibit no clinical signs of cancer for many years. The way forward for this class of novel agents lies in our ability to understand human immune responses in the tumor microenvironment… Expand

Topics from this paper

Paper Mentions

Interventional Clinical Trial
This is a randomized, open-label, adaptive, two arm, multicentre, Phase II trial comparing a neoadjuvant chemotherapy with PDL1-inhibition (Atezolizumab) and Atezolizumab two-week… Expand
ConditionsTriple-negative Breast Cancer
InterventionDrug, Procedure
Interventional Clinical Trial
Open label, phase I-II study to evaluate the safety and activity of intratumoral urelumab combined with systemic nivolumab in patients with advanced solid tumors. Serial tumor and… Expand
ConditionsNeoplasms
InterventionDrug
Interventional Clinical Trial
This pilot phase I trial aims to investigate the safety and tolerability of anti-programmed cell death-1 (PD-1) monoclonal antibody Sintilimab (also called IBI308) in combination with… Expand
ConditionsStage IV NSCLC
InterventionDrug, Radiation
Alternative Checkpoints as Targets for Immunotherapy
TLDR
Alternative checkpoints that can be targeted to improve cytotoxic lymphocyte function while harnessing other components of the immune system are discussed. Expand
Delivery Strategies for Immune Checkpoint Blockade
TLDR
A brief review summarizes strategies to increase the antitumor immunity, including the local and targeted delivery of checkpoint inhibitors, and a combination of different checkpoint inhibitors or with other therapeutic treatments. Expand
Immune Checkpoint Therapy and the Search for Predictive Biomarkers
TLDR
More work is needed to provide a better understanding of the mechanisms that elicit tumor rejection, which will enable identification of appropriate biomarkers, reveal new targets, provide data to guide combination studies, and eventually dictate a platform that allows more patients to derive clinical benefit with immune checkpoint therapy. Expand
Emerging predictors of the response to the blockade of immune checkpoints in cancer therapy
TLDR
The current state and progress of predictors as aids in checkpoint blockade-based immunotherapy in cancer is discussed, with a focus on tumor mutational burden and peripheral blood biomarkers. Expand
Targeting the tumor microenvironment to overcome immune checkpoint blockade therapy resistance.
TLDR
A briefly succinct glimpse into the most exciting pre-clinical discoveries and ongoing clinical trials to overcome the resistance of ICIs are provided. Expand
Lessons learned from the blockade of immune checkpoints in cancer immunotherapy
TLDR
The current understanding of the mechanisms by which resistance to checkpoint blockade immunotherapy occurs is summarized, and how actionable combination strategies may be derived to improve clinical outcomes for patients is outlined. Expand
Reinstating endogenous antitumor immunity: The concept of therapeutic management of cancer
TLDR
By understanding the immune tumor microenvironment, this work can now target key pathways that suppress endogenous antitumor responses, thereby re-instating such immune responses and identifying novel targets for immune therapies. Expand
Current Strategies to Enhance Anti-Tumour Immunity
TLDR
This review summarizes the recent advances in immune therapies and discusses the importance of combination therapies in the treatment of cancers. Expand
Regulation of Cancer Immune Checkpoints: Molecular and Cellular Mechanisms and Therapy
Cancer immunotherapy, especially immune checkpoint blockade therapy, represents a hotspot in cancer research. However, the low response rate, adaptive/acquired resistance, and adverse effects stillExpand
Enhancing T cell therapy by overcoming the immunosuppressive tumor microenvironment.
TLDR
Emerging findings on the main negative circuits limiting the efficacy of cancer immunotherapy are reviewed, as well as novel and conventional approaches that can translate into rational combination therapies. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 70 REFERENCES
Combining Radiation and Immunotherapy: A New Systemic Therapy for Solid Tumors?
TLDR
A comprehensive overview of the early clinical and preclinical evidence behind the combination of immunomodulating agents with radiation to induce a phenomenon known as the abscopal effect, whereby localized radiation results in immune-mediated tumor regression in disease sites well outside of the radiation field. Expand
The blockade of immune checkpoints in cancer immunotherapy
  • D. Pardoll
  • Biology, Medicine
  • Nature Reviews Cancer
  • 2012
TLDR
Preliminary clinical findings with blockers of additional immune-checkpoint proteins, such as programmed cell death protein 1 (PD1), indicate broad and diverse opportunities to enhance antitumour immunity with the potential to produce durable clinical responses. Expand
Neoantigens in cancer immunotherapy
TLDR
Observations indicate that neoantigen load may form a biomarker in cancer immunotherapy and provide an incentive for the development of novel therapeutic approaches that selectively enhance T cell reactivity against this class of antigens. Expand
Novel cancer immunotherapy agents with survival benefit: recent successes and next steps
TLDR
The following next steps are necessary: first, the development of immune-monitoring strategies for the identification of relevant biomarkers; second, the establishment of guidelines for the assessment of clinical end points; and third, the evaluation of combination therapy strategies to improve clinical benefit. Expand
Cancer immunotherapy: moving beyond current vaccines
TLDR
Results in cancer vaccine trials are considered and alternate strategies that mediate cancer regression in preclinical and clinical models are highlighted. Expand
Localized Oncolytic Virotherapy Overcomes Systemic Tumor Resistance to Immune Checkpoint Blockade Immunotherapy
Intratumoral treatment with an oncolytic virus results in inflammatory infiltrates in distant tumors and sensitizes the tumors to immune-mediated rejection in the setting of immunotherapy with CTLA-4Expand
Enhancement of Antitumor Immunity by CTLA-4 Blockade
TLDR
In vivo administration of antibodies to CTLA-4 resulted in the rejection of tumors, including preestablished tumors, and this rejection resulted in immunity to a secondary exposure to tumor cells, suggesting that blockade of the inhibitory effects of CTLA4 can allow for, and potentiate, effective immune responses against tumor cells. Expand
CTLA-4 blockade increases IFNγ-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients
TLDR
It is found that CD4 T cells from peripheral blood and tumor tissues of all treated patients had markedly increased expression of inducible costimulator (ICOS), which are the first immunologic changes reported in both tumor tissues and peripheral blood as a result of treatment with anti-CTLA-4 antibody. Expand
PD-1 blockade induces responses by inhibiting adaptive immune resistance
TLDR
It is shown that pre-existing CD8+ T cells distinctly located at the invasive tumour margin are associated with expression of the PD-1/PD-L1 immune inhibitory axis and may predict response to therapy. Expand
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients
TLDR
It is shown that periodic infusions of anti-CTLA-4 antibodies after vaccination with irradiated, autologous tumor cells engineered to secrete GM-CSF (GVAX) generate clinically meaningful antitumor immunity without grade 3 or 4 toxicity in a majority of metastatic melanoma patients. Expand
...
1
2
3
4
5
...